A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A PARTICIPANTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) STUDY TO ASSESS THE ACTIVITY, SAFETY, AND TOLERABILITY OF SAR445399 IN ADULT
- Registry ID
- PDY19372
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Start date
- 2026-07-09
- Last update
- 2026-03-20
Conditions
- NON-CYSTIC FIBROSIS BRONCHIECTASIS
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PROOF-OFCONCEPT (POC) STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF
ITEPEKIMAB, IN PARTICIPANTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS
- A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK, PHASE III STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS (MAHALE)
View on source registry